Dosing & Uses
Dosage Forms & Strengths
tablets
- 4mg
- 8mg
- 12mg
tablets, extended-release
- 8mg
- 16mg
- 24mg
oral solution
- 4mg/mL
Alzheimer Disease
Initial
- Conventional: 4 mg PO q12hr
- ER: 8 mg PO qAM
Maintenance
- Conventional: Titrate to 8-12 mg PO q12hr; increase by 4 mg q12hr at no less than 4 week intervals
- ER: 16-24 mg PO qAM; increase by 8 mg/d at no less than 4 week intervals
Hepatic Impairment
Moderate: (Child-Pugh score 7-9): Not to exceed 16 mg/day
Severe: Not recommended
Renal Impairment
Moderate: Not to exceed 16 mg/day
Severe (CrCl <9 mL/min): Not recommended
Administration
Take with food
Conversion from galantamine tablets and oral solution to galantamine ER should occur at same daily dosage with the last dose of galantamine tablets/oral solution taken in evening and starting galantamine ER once daily treatment next morning
Not recommended
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Nausea (20-25%)
Diarrhea (11-15%)
Vomiting (11-15%)
1-10%
Abdominal pain
Anorexia
Muscle cramp
Fatigue
Dizziness
Headache
Weight loss
Depression
Insomnia
UTI
Somnolence
Anemia
Syncope
Bradycardia
Other Information
Complete atrioventricular block
Warnings
Contraindications
Hypersensitivity
Cautions
Moderate hepatic or renal impairment: max 8 mg q12hr (conventional) or 16 mg qDay (ER)
Not recommended in severe hepatic or renal impairment
Dose-related increase in risk of syncope reported
Renamed Razadyne from Reminyl in the US to avoid confusion with Amaryl
Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) reported; inform patients and caregivers that therapy should be discontinued at first appearance of skin rash, unless rash is clearly not drug-related; do not resume treatment and consider alternative therapy if signs or symptoms suggest a serious skin reaction
As a cholinesterase inhibitor, therapy is likely to exaggerate neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia
All patients should be considered at risk for adverse effects on cardiac conduction, including bradycardia and AV block, due to vagotonic effects on sinoatrial and atrioventricular nodes; cholinesterase inhibitors have vagotonic effects on sinoatrial and atrioventricular nodes, leading to bradycardia and AV block; bradycardia and all types of heart block have been reported in patients both with and without known underlying cardiac conduction abnormalities
Cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity; monitor patients closely for symptoms of active or occult gastrointestinal bleeding, especially those with increased risk for developing ulcers, eg, those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDs)
Cholinomimetics may cause bladder outflow obstruction
Use caution when prescribing to patients with a history of severe asthma or obstructive pulmonary disease; monitor respiratory function closely for occurrence of respiratory adverse effects
Cholinesterase inhibitors are believed to have potential to cause generalized convulsions; seizure activity may also be a manifestation of Alzheimer’s disease; patients with Alzheimer’s disease should be monitored closely for seizures while receiving therapy
Due to pharmacological properties, therapy may cause nausea, vomiting, diarrhea, anorexia, and weight loss; monitor patient’s weight during therapy
Individuals with mild cognitive impairment demonstrate isolated memory impairment greater than expected for their age and education, but do not meet current diagnostic criteria for Alzheimer’s disease
Pregnancy & Lactation
Pregnancy
There are no adequate data on developmental risk associated with use in pregnant women
Animal data
- In studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically
Lactation
There are no data on presence of ddrug in human milk, effects on breastfed infant, or on milk production
Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for drug and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Derived from daffodil bulbs
Increases acetylcholine from surviving presynaptic nerve terminals by modulating the nicotinic acetylcholine receptor. Glutamate and serotonin levels may increase
Pharmacokinetics
Half-Life: 7 hr
Peak Plasma Time: 1 hr
Bioavailability: 90%
Protein Bound: 18%
Vd: 175 L
Metabolism: CYP2D6 & CYP3A4
Excretion: Urine
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.